About
Genentech, Inc. (Genentech) is a biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for unmet medical needs. The Company manufactures and commercializes multiple biotechnology products, and receives royalties from companies that are licensed to market products based on its technology. Genentech commercializes various products in the United States, including Avastin, Rituxan, Herceptin, Lucentis, Xolair, Tarceva, Nutropin, Activase, TNKase, Cathflo Activase, Pulmozyme and Raptiva. The Company’s licensed products include Trastuzumab, Rituximab, Bevacizumab, Dornase alfa, recombinant, Alteplase and Tenecteplase, Somatropin, Etanercept, D2E7/adalimumab, Infliximab, Cetuximab and Antihemophilic factor, recombinant. On December 8, 2006, Lonza Group AG acquired Genentech's mid-scale mammalian biopharmaceutical production plant in Porrino, Spain.
$73.7 (08/23/07)
